Background: Vitiligo is a chronic disease characterized by the appearance of achromic macules caused by melanocyte destruction. Surgical treatments with melanocyte transplantation can be used for stable vitiligo cases. oBjectives: To evaluate treatment response to the autologous transplantation of noncultured epidermal cell suspension in patients with stable vitiligo. Methods: Case series study in patients with stable vitiligo submitted to noncultured epidermal cell suspension transplantation and evaluated at least once, between 3 and 6 months after the procedure, to observe repigmentation and possible adverse effects. The maximum follow-up period for some patients was 24 months. results: Of the 20 patients who underwent 24 procedures, 25% showed an excellent rate of repigmentation, 50% good repigmentation, 15% regular, and 10% poor response. The best results were observed in face and neck lesions, while the worst in extremity lesions (88% and 33% of satisfactory responses, respectively). Patients with segmental vitiligo had a better response (84%) compared to non-segmental ones (63%). As side effects were observed hyperpigmentation of the treated area and the appearance of Koebner phenomenon in the donor area. study liMitations: Some limitations of the study included the small number of patients, a subjective evaluation, and the lack of long-term follow-up on the results. conclusion: Noncultured epidermal cell suspension transplantation is efficient and well tolerated for stable vitiligo treatment, especially for segmental vitiligo on the face and neck.
INTRODUCTION
Vitiligo is a chronic acquired and progressive disease, characterized by the appearance of achromic macules that are isolated or found in multiple body segments, due to the absence of melanin caused by the destruction or functional loss of melanocytes. These lesions can appear on any part of the body, such as the face and neck, hands, feet, legs, genitals, and hairs. 1 The world prevalence of vitiligo has been estimated at between 0.5% and 2%, and can affect individuals from both genders and all types of skin. 2 The disease can affect individuals of different ages, but it generally begins at around 22 years of age in the USA, 25 in England, and 24 in Brazil. 1, 3 Vitiligo entails a considerable psychological impact as well as an impact on the quality of life of the affected individuals, which can result in relationship problems, low self-esteem, high levels of anxiety, and even depression. 4, 5 According to the review released by the Vitiligo Global Issues Consensus
Conference between 2011 and 2012, vitiligo can be classified in three forms: non-segmental vitiligo (NSV), a group which includes the acrofacial, mucosa, generalized, universal and mixed forms; segmental vitiligo (SV), which can be unisegmental, bisegmental, or multisegmental; and the unclassified or undetermined form. 6, 7 The clinical evolution of vitiligo is unpredictable, and the pathogenic mechanisms involved have yet to be fully understood.
Nearly one-third of the patients with vitiligo have a family history of the disease, and genetic studies have demonstrated an association with other auto-immune diseases, such as thyroid disease, diabetes, pernicious anemia, Addison's disease, rheumatoid arthritis, among others. 2, 8 The association between vitiligo and the haplotypes of tem act together and end up provoking the death of melanocytes, seems to play an important role in the pathogenesis of vitiligo and is currently the most well-accepted among specialists. 1, 7 The immunological activity also seems to be involved in the capacity of response to the different types of therapeutic approaches to treat vitiligo. [10] [11] [12] There are many surgical and non-surgical therapeutic approaches used to treat vitiligo, but none can guarantee the complete and long-lasting disappearance of the disease. The main approaches include treatments with corticosteroids as well as topical and orally administered immunomodulators; phototherapy with sunlight, UVA, PUVA, UVB radiation, especially of narrow band (NB-UVB), and excimer lasers. Some antioxidants and other natural products, such as Polypodium leucotomos, can also be used, mainly in association with other treatments.
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Surgical treatments may be recommended as the treatment of choice for cases of segmental vitiligo, as well as for patients with a stable disease and who did not respond well to the other types of treatment. Surgery can also be recommended for areas of difficult treatment, including the hands, feet, and mucosa. Skin grafts and epidermal cell suspensions are the most commonly applied approaches. 14 The transplantation of epidermal cells in suspension can be performed with cultivated cells, but this would require a longer period of time, more laboratory resources, and high costs. Moreover, it is difficult to guarantee the feasibility of the culture. By contrast, larger areas can be treated. In the non-cultured cell transplants, these can be obtained by scraping, curettage, suction blister, or by removal of a thin layer of skin with a Blair blade or other resection techniques. 15 The transplantation of epidermal cell suspension (melanocytes and keratinocytes) has been used and documented by different groups, primarily in Asia, the Middle East, and Europe, as well as in some groups in Brazil. [13] [14] [15] [16] [17] [18] The aim of the present study is to evaluate the patient response with stable vitiligo in different areas of the body for treatment with the transplantation of noncultured epidermal cell suspension. and not to practice activities that could cause perspiration or that would wet the treated areas. The patients returned to the doctor's office after seven days and the dressings were removed. It was recommended for the patient to expose the treated area to sunlight for 10 minutes daily.
METHODS
The patients were evaluated between 3 and 12 months after the procedure. The change in pigmentation was evaluated, by a dermatologist on the patient and in comparison with photographs taken before and after the procedure. The repigmentation rates were determined through a previously described scoring system: excellent (≥ 90% repigmentation), good (50 to 89% repigmentation), regular (20 to 49% repigmentation), and poor (< 20% repigmentation).
The rate considered satisfactory was greater than 50% of repigmentation (sum of the results considered excellent and good), such as that used by researchers. Results of excellent repigmentation were observed in 25% of the patients. Ten patients (50%) presented a good rate of repigmentation, 15% presented regular repigmentation, and 10% presented a poor response (Figure 1 ). Of the total of treated patients, 75% obtained a satisfactory result (>50% repigmentation).
RESULTS

During
The repigmentation rates, according to the location of the lesions, are presented in table 3. The best responses were observed in the face and neck regions, with 37.5% presenting an excellent response (≥ 90% repigmentation) and 50% presenting a good result (50 to 89% repigmentation). For the lesions identified on the limbs, the results were also considered satisfactory (20% excellent and The main adverse event associated with the procedure was pain due to the anesthetic infiltration in the donor area, and especially in the dermabrasion area (previously prepared with topical anesthetic cream, occluded for 30 minutes), in addition to burning during the placing of the collagen dressing. In general, the procedure was well tolerated and the majority of the patients appeared to be willing to undergo the procedure again, if necessary. The pain after the procedure occurred mainly in the most sensitive areas, and none of the patients developed infections in donor or receptor areas.
One case of Koebner phenomenon appeared in the donor region (thigh) ( Figure 5 ). Hyperchromia in the receptor area in two patients and slight hypopigmentation in another patient also were observed.
The uniform coloration was obtained in the majority of the receptor areas of other patients. FIgure 2 : Evaluation of repigmentation in patients with segmental vitiligo (n=12) and non-segmental vitiligo (n=8). Excellent = ≥ 90%, Good = 50 to 89%, Regular = 20 to 49%, and Poor = < 20% is five times greater than the donor area.
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The technique used in the present study was that defined by
Olsson & Juhlin in 1998 and later modified by Mulekar in 2004. 19, 23 In scientific literature, it is possible to find different modifications in the methodology of this procedure, from the manner in which to obtain the cells from the donor area, to the preparation of the receptor area, to the types of dressings used. Epidermal cells can be obtained by resection of a thin layer of skin, using a flexible blade, through the epidermal curettage or through manual dermabrasion. 18, 21, 24 The receptor area can be prepared by manual or motorized dermabrasion device, CO 2 lasers, liquid nitrogen, among others. 25 One recent arti- ing excellent results and 31% presenting good results. 22 One recent study conducted by Komen et al. (2015) , using the ReCell™ device to obtain cell suspension, reported a satisfactory response in 60% of the patients, which was also slightly lower than that observed in the present study. 27 A greater percentage of satisfactory responses was observed by Bao et al. (2015) when treating patients with segmental and non-segmental vitiligo with melanocyte transplantation. 20 The authors observed 53% of the results with excellent repigmentation and 28% with good repigmentation, with noncultured cell suspension. In their study, the authors also compared three different surgical techniques, treating, in the same session, the lesion area divided into three parts (suction blistering grafting, cultured epidermal cell suspension transplantation, and noncultured cell transplantation).
They concluded that the three methods are safe and efficient and should be chosen according to the size and location of the lesions and available laboratory resources. 20 Although there are some differences in the responses observed by different groups that used similar transplant methods, there is a consensus that some factors, such as the type of vitiligo, can determine the greater or lesser success of the treatment. Mulekar et al. suggest that in patients with segmental vitiligo it is possible to achieve a nearly 95% repigmentation by applying noncultured melanocyte/keratinocyte transplantation, with a low recurrence of lesions in the treated patients. 28 However, when these same authors treated patients with non-segmental vitiligo, the success rates were reduced to 67%. 29 In the present study, this tendency was also observed, with better rates of satisfactory repigmentation in patients with segmental vitiligo (34% excellent and 50% good).
The location of the lesions is a determining factor in the success of different modalities of treatment for vitiligo. In this study, the best repigmentation rates were observed in the lesions located in the face and cervical regions, followed by the limbs (arms and legs). The worst results were observed in the trunk and extremities (hands and feet Many of these differences still cannot be fully explained due to the complex mechanisms related to the pathogenesis of the vitiligo and to diverse factors that can influence the course and response to different treatments.
The main adverse effects noted in the patients treated with epidermal cell suspension in the present study included pain and discomfort during the stages of the procedure and in the immediate post-operative stage. Greater complications were not observed, such as infections and scars in the donor/receptor areas. The majority of patients reported satisfaction with the methods and availability to undergo the procedure again, if necessary. This study identified one patient with the appearance of Koebner phenomenon in the donor area, while another patient presented hyperpigmentation with depigmented edges in the receptor area. These effects have also been observed in other studies. 22, 28, 32 The possibility of the occurrence of these effects should be explained to the patients before beginning the procedure.
Vitiligo is a multifactorial disease of complex pathogenesis that is not fully understood, as it is difficult to explain the difficulty of repigmentation in some locations and even in cases which would apparently have a good chance of response, but that present no significant improvement.
One important factor in the selection of patients for surgical treatment with epidermal cell suspension is the stability of the dis- increase in the quantity of T CD8+ and CD45RO+ lymphocytes in the vitiligo lesion areas, and this increase was related to the lower stability and worse response to treatment with melanocyte transplants. 33 The presence of cytotoxic lymphocytes in the skin lesions has also been demonstrated by other studies. 35, 36 In addition to the immunological mechanisms that act in the site, the systemic immunological state of the patient can also influence the pathogenesis and the results of the treatment for vitiligo. The presence of anti-melanocyte antibodies; the increase in pro-inflammatory cytokines, such as the tumor necrosis factor and interferon gamma; and the changes in regulatory T cells also seem to play an important role. 7, 37, 38 Other factors, such as molecular characteristics of suspension cells and
